AI Article Synopsis
- Researchers are exploring ways to achieve immune tolerance in organ transplants to reduce the toxicity of chronic immunosuppressive drugs.
- They developed a method using a bioengineered cellular product combined with nonmyeloablative conditioning, which showed successful engraftment and immune tolerance in patients receiving mismatched kidney transplants.
- Among the eight recipients, five maintained durable chimerism and were able to stop all immunosuppression without serious complications, indicating a promising approach for safer transplants.
Article Abstract
The toxicity of chronic immunosuppressive agents required for organ transplant maintenance has prompted investigators to pursue approaches to induce immune tolerance. We developed an approach using a bioengineered mobilized cellular product enriched for hematopoietic stem cells (HSCs) and tolerogenic graft facilitating cells (FCs) combined with nonmyeloablative conditioning; this approach resulted in engraftment, durable chimerism, and tolerance induction in recipients with highly mismatched related and unrelated donors. Eight recipients of human leukocyte antigen (HLA)-mismatched kidney and FC/HSC transplants underwent conditioning with fludarabine, 200-centigray total body irradiation, and cyclophosphamide followed by posttransplant immunosuppression with tacrolimus and mycophenolate mofetil. Subjects ranged in age from 29 to 56 years. HLA match ranged from five of six loci with related donors to one of six loci with unrelated donors. The absolute neutrophil counts reached a nadir about 1 week after transplant, with recovery by 2 weeks. Multilineage chimerism at 1 month ranged from 6 to 100%. The conditioning was well tolerated, with outpatient management after postoperative day 2. Two subjects exhibited transient chimerism and were maintained on low-dose tacrolimus monotherapy. One subject developed viral sepsis 2 months after transplant and experienced renal artery thrombosis. Five subjects experienced durable chimerism, demonstrated immunocompetence and donor-specific tolerance by in vitro proliferative assays, and were successfully weaned off all immunosuppression 1 year after transplant. None of the recipients produced anti-donor antibody or exhibited engraftment syndrome or graft-versus-host disease. These results suggest that manipulation of a mobilized stem cell graft and nonmyeloablative conditioning represents a safe, practical, and reproducible means of inducing durable chimerism and donor-specific tolerance in solid organ transplant recipients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3610325 | PMC |
| http://dx.doi.org/10.1126/scitranslmed.3003509 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Post-transplant transient abnormal myelopoiesis evolving from a GATA1 mutant clone in umbilical cord blood.
Ann Hematol
December 2024
Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Transient abnormal myelopoiesis (TAM) generally affects newborns with Down syndrome and is associated with constitutional trisomy 21 and a somatic GATA1 mutation. Here we describe a case of TAM which evolved after umbilical cord blood transplantation (UCBT), whose origin was identified as a GATA1 mutation-harboring clone in umbilical cord blood (UCB) by detailed genetic analyses. A 58-year-old male who received UCBT for peripheral T-cell lymphoma presented progressive anemia and thrombocytopenia, and leukocytosis with blast cells in the peripheral blood (PB).
View Article and Find Full Text PDFCellular trafficking and fate mapping of cells within the nervous system after in utero hematopoietic cell transplantation.
Commun Biol
December 2024
Washington University in St. Louis School of Medicine, Department of Surgery, Division of Pediatric Surgery, St. Louis, MO, USA.
Article Synopsis
- - In utero hematopoietic cell transplantation (IUHCT) takes advantage of the fetus's immune tolerance to successfully introduce donor cells without prior conditioning or immunosuppression, aiming for long-lasting cell integration.
- - A study injected adult bone marrow cells into fetal mice at gestational ages 12-17 days, finding the highest concentration of donor cells in the brain when injected between GA 13-14, with significant persistence of these cells in the hindbrain.
- - This research is groundbreaking as it details how donor cells migrate into the nervous system during fetal development, laying the groundwork for using IUHCT to potentially treat neurogenetic disorders.
Durable mixed chimerism may permit subsequent immunosuppression-free intestinal transplantation-A proof-of-principle study.
Am J Transplant
October 2024
Columbia Center of Translational Immunology, Department of Medicine, Columbia University, New York, New York, USA; Department of Surgery, Columbia University/New York-Presbyterian Hospital, New York, New York, USA. Electronic address:
Intestinal transplantation (ITx) is the definitive treatment for intestinal failure but has the highest rejection rate among solid organ transplants, requiring high doses of immunosuppressive medication, which is associated with high rates of infection, graft-versus-host disease, and malignancy. Transplant tolerance would overcome the need for long-term immunosuppression (ISP). Using nonmyeloablative conditioning, our laboratory has developed a novel swine model of hematopoietic stem cell transplantation (HSCT) that produces durable mixed chimerism (MC) and immune tolerance without toxicity.
View Article and Find Full Text PDFSuccessful Cord Blood Transplantation for Myeloid/Natural Killer Precursor Acute Leukemia: A Case Report and Literature Review.
Intern Med
September 2024
Department of Hematology, Tohoku University Hospital, Japan.
A 21-year-old man was diagnosed with myeloid/natural killer precursor leukemia (MNKPL) with bone marrow infiltration of blasts of cyCD3, CD7, CD33, CD34, CD56, HLA-DR, cyMPO, and TdT immunophenotypes. Although hyper-CVAD therapy was unsuccessful, induction treatment with idarubicin and cytarabine resulted in complete remission (CR). The patient subsequently underwent cord blood transplantation with a myeloablative conditioning regimen, which resulted in durable CR and complete donor chimerism.
View Article and Find Full Text PDFAt-Labeled Anti-CD45 Antibody as a Nonmyeloablative Conditioning for Canine DLA-Haploidentical Stem Cell Transplantation.
J Nucl Med
September 2024
Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington.
The α-emitter At deposits a high amount of energy within a few cell diameters, resulting in irreparable DNA double-strand breaks while minimizing off-target toxicity. We investigated the use of the At-labeled anti-CD45 monoclonal antibody (mAb) At-CD45-B10 as a nonmyeloablative conditioning regimen for dog-leukocyte-antigen-haploidentical hematopoietic cell transplantation. Seventeen healthy dogs were injected with either a 0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!